Kligerman M M, Shaw M T, Slavik M, Yuhas J M
Cancer Clin Trials. 1980 Fall;3(3):217-21.
Toxicity studies of S-2-(3 aminopropylamino)-ethylphosphorothioic acid (WR-2721) access patients in remission following radiation therapy. The dose has been escalated from 25 to 250 mg/m2 without significant symptoms. Inconsistent variation in the systolic blood pressure in some patients has been observed over an 8-10-point range without producing any symptoms. The variation could be within the patient's normal range. However, tests are planned to rule out cardiac toxicity or peripheral vascular reaction. Combining WR-2721 with conventional radiotherapy is contemplated by intravenous injection of the drug 20-30 minutes before irradiation. This will start as weekly injections, and the number of weekly injections will be increased progressively. Animal studies suggest that the level already safely reached could give significant protection to the normal tissues without protecting tumor.
对S-2-(3-氨丙基氨基)-乙硫代磷酸（WR-2721）进行毒性研究，受试对象为放疗后处于缓解期的患者。剂量已从25毫克/平方米逐步增至250毫克/平方米，未出现明显症状。在部分患者中观察到收缩压有8 - 10个点的不一致变化，但未产生任何症状。这种变化可能在患者的正常范围内。不过，计划进行测试以排除心脏毒性或外周血管反应。考虑在放疗前20 - 30分钟静脉注射WR-2721，将其与传统放疗相结合。开始时每周注射一次，每周注射次数将逐渐增加。动物研究表明，已安全达到的剂量水平可对正常组织提供显著保护，而不会保护肿瘤。
